EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptide 6a a fibrin ogen degradation products increases coronary blood flow






American Journal of Physiology 249(3 PART 2): H457-H462

Peptide 6a a fibrin ogen degradation products increases coronary blood flow

The coronary hemodynamic effects of intracoronary administration of a fibrin(ogen)-derived pentapeptide, Ala-Arg-Pro-Ala-Lys (peptide 6A), were evaluated in open-chest anesthetized dogs. With administration of peptide 6A (2.5-30 .mu.mol), coronary blood flow increased and coronary vascular resistance decreased promptly in a dose-related manner. Increase in coronary blood flow was independent of any change in indexes of myocardial O2 demand, indicating the peptide 6A exerts direct effects on coronary arterial tone. Systemic arterial and left ventricular end-diastolic pressures remained unchanged with smaller doses but decreased when higher doses of peptide 6A (.gtoreq. 20 .mu.mol) were administered. Plasma concentrations of 6-ketoprostaglandin F1.alpha., stable hydrolysis product of prostacyclin, increased in coronary sinus blood samples in conjunction with increase in coronary blood flow. Administration of indomethacin (5 mg/kg iv) inhibited peptide 6A-induced release of prostacyclin and significantly attenuated the effects of peptide 6A on coronary hemodynamics. Pretreatment of animals with H2-receptor blocker cimetidine (500 mg iv) or with H1- and H2-receptor blocker diphenhydramine (50 mg iv) had no significant effects on peptide 6A-induced increase in coronary blood flow. This study suggests that this fibrin(ogen)-derived peptide has potent vasodilator effects on the coronary vascular bed of the dog, and these effects are in part mediated by stimulation of prostacyclin release.


Accession: 006079609

PMID: 3839977



Related references

Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. Acta Physiologica Scandinavica 142(3): 339-344, 1991

Fibrin(ogen)-derived peptide B beta 30-43 increases coronary blood flow in the anesthetized dog. Thrombosis Research 39(2): 223-229, 1985

Effect of internal hemorrhage on fibrin(ogen) degradation products in canine blood. American Journal of Veterinary Research 47(7): 1620-1621, 1986

Effect of fibrin(ogen) degradation products on blood viscosity values during thrombolysis. Clinical Hemorheology 13(1): 13-22, 1993

Use of monoclonal antibodies to fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. NATO ASI series Series A Life sciences19(219): 189-197, 1991

The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemporary Oncology 17(2): 113-119, 2013

Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 9(1): 109-121, 1989

Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients. Chinese Medical Journal 128(6): 727-732, 2015

Content of soluble fibrin monomeric complexes, factor XIII and fibrin(ogen) degradation products in neonatal asphyxia. Archives of Gynecology 228(1-4): 626-627, 1979

Ca binding of rat fibrinogen and fibrin(ogen) degradation products. Febs Letters 93(1): 177-180, 1978